Performance Enhancing Product UsePERB12NCT06639789
Effect of a New Formulation of Vitamin B12 on Physical and Mental
A study testing Vitamin B12 (B12) in people with Performance Enhancing Product Use, run by Francisco Javier Martínez Noguera at 1 site in Spain.
Trial summary
This clinical study evaluates the effect of acute intake of a new vitamin B12 formulation on anaerobic and cognitive performance variables. One of the limiting factors for the potential beneficial effects of vitamin B12 is its bioavailability. Read more about this study
- Who is it for?
- Ages 18 to 45 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Performance Enhancing Product Use
- What is being tested?
- Vitamin B12 (B12)
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 18 participants
- Where
- 1 siteSpain
- Study dates
- 1 Jul 2024to 31 Dec 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Male cyclists who have competed in both junior and amateur categories.
- Cycling between 6-15 hours of training per week.
- BMI between 18-25 kg/m2.
Who cannot join
- Smokers or regular alcohol drinkers.
- Persons suffering from a metabolic, cardiorespiratory or digestive pathology or anomaly.
- digestive system.
- People who have suffered an injury in the last 6 months that limits the performance of the study tests. of the study tests.
- People taking supplements or medication in the 2 weeks before the start of the study.
Trial locations and contacts
1 site in 1 country.
Spain1 site, 1 recruiting
- Recruiting
Research Center for High Performance Sport. Catholic University of Murcia
La Ñora, Murcia, 30830
Francisco Javier Martínez Noguera, PhD, (+34) 646666782, fjmartinez3@ucam.edu
Cristian Marín Pagán, PhD, (+34) 968278566, cmarin@ucam.edu
About this study
Official title: Evaluation of the Effect of a New Formulation of Vitamin B12 on Physical and Mental Performance in Trained Cyclists.
This clinical study evaluates the effect of acute intake of a new vitamin B12 formulation on anaerobic and cognitive performance variables. One of the limiting factors for the potential beneficial effects of vitamin B12 is its bioavailability. This new formula improves this aspect, so that by improving plasma levels of B12 we will be able to relate whether this situation may be related to improved performance or cognitive tasks.
Read the detailed description
Participants
All participants were informed about the procedures and provided signed informed consent. The study was conducted in accordance with the guidelines of the Declaration of Helsinki Declaration for Research Involving Human Subjects and the protocol was approved by the Institutional Review/Ethics Committee of the Catholic University of Murcia (Code: CE052416).
Study design
Randomized, double-blind, placebo-controlled, crossover clinical trial with 2 study groups (vitamin B12 and placebo). Cyclists were instructed to take the supplement (vitamin B12 or placebo) with breakfast on the three days before the tests and 3h before the test day, and to continue with their usual diet and training programme. Subjects in both groups were instructed not to consume vitamin B12-rich foods for 7 days before and during the study. Between each intervention (B12 and Placebo) there was a 7-day washout period.
Procedures
Participants visited the laboratory on three occasions. Visit 1 consisted of a medical examination and a blood draw to determine health status. At visits 2 and 3, a 24-hour diet reminder and a Wingate test, mental fatigue test and venous blood draw were performed. The sports nutritionist prescribed a standardized breakfast before each testing session (visits 2 and 3).
Pre- and post-evaluation test
Visit 1:
Health status blood test: A general blood test will be performed both pre- and post-supplementation. The blood will be drawn through a vein (fasting).
Medical examination: A medical history of family and personal history, an electrocardiogram (ECG) at rest and a medical examination (auscultation, blood pressure, etc.) will be carried out to certify that the person is healthy and does not present a risk to participate in the study (Fasting).
Body composition by absorptiometric densitometry (DXA): A body composition test will be performed using the double energy absorptiometric densitometry technique (X-rays), with the aim of determining parameters of fat mass, fat-free mass and fat percentage. In addition, anthropometry will also be used to determine changes in body composition (fat and muscle mass) (Fasting).
Visits 2 and 3:
Anaerobic power and mechanical power output: After a standardised breakfast, a Wingate test was performed on a cycle ergometer. The Wingate test (WAnT) consisted of a 30 s sprint on a cycle ergometer (Monark Ergomedic 894E Peak Bike, Vansbro, Sweden). Breaking strength was held constant at 7.5% of each individual's body mass. All participants were verbally encouraged to pedal as fast as possible throughout the sprint.
Mental fatigue test: All participants will be tested for the evaluation of reaction time to a sequence of lights set by the investigator before and after the performance test.
Biochemical markers: A venous blood draw will be performed by medical personnel before and after the performance test, in which vitamin B12, creatine kinase and lactate dehydrogenase levels will be analyzed.
All data of the subjects who participated in the study were stored in a computer system with a security key. In addition, some of the data was also recorded on paper and kept under lock and key, accessible only to the researchers of this project.
- Conditions
- Performance Enhancing Product Use
- Being tested
- Vitamin B12 (B12), PLACEBO (PLA)
- Keywords
- Anaerobic performance, Power, Mental fatigue, Vitamins, Recovery
- Medical subject headings
- Mental Fatigue
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Vitamin B12 (B12)Dietary supplement
The new formulation of vitamin B12 will be ingested 3 days before and on the day of testing (3 hours before).
PLACEBO (PLA)Dietary supplement
The placebo will be ingested 3 days before and the same day of the tests (3 hours before).
| Study group | Role | What they receive |
|---|---|---|
| Vitamin B12 (B12) | Experimental | Subjects in this group will intake 1 mg/day of vitamin B12 three days before the tests. Receives: Dietary Supplement: Vitamin B12 (B12) |
| PLACEBO (PLA) | Placebo comparator | Subjects in this group will intake 200 mg/day of microcrystalline cellulose three days before the tests. Receives: Dietary Supplement: PLACEBO (PLA) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Wingate test
This test consists of 5 efforts of 30 seconds at maximum intensity with a recovery of 3 minutes on a bike. In this test the peak and average power of each effort and the total average will be evaluated. In addition, the time to maximum peak power and the fatigue index.
Measured: Throughout study completion, an average of 3 weeks
Secondary outcomes (3)
Mental fatigue test
In this test, we will measure the speed of reaction in the resolution of a sequence of lights set by the researcher before and after the end of the performance test.
Measured: Throughout study completion, an average of 3 weeks
Biochemical markers
Vitamin B12, creatine kinase and lactate dehydrogenase concentrations are also measured before and after the performance tests.
Measured: Throughout study completion, an average of 3 weeks
Sleep Quality Questionnaire (Pittsburgh)
The questionnaire will be carried out 3 days before and one day after the performance tests.
Measured: Throughout study completion, an average of 3 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Oct 2024
- Study start1 Jul 2024
- Primary completion30 Nov 2024 (estimated)
- Study completion31 Dec 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Performance Enhancing Product UseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- A randomized crossover study will be conducted in which 18 subjects will perform the following conditions: B12) 1 mg/d vitamin B12; PLA) 200 mg/d placebo (microcrystalline cellulose) 3 days before physical and cognitive performance tests.
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 18 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Francisco Javier Martínez Noguera
- Sponsor type
- University, hospital or other
- Collaborators
- Universidad Católica San Antonio de Murcia
- Responsible party
- Sponsor-investigator, Francisco Javier Martínez Noguera, Universidad Católica San Antonio de Murcia
- Investigators
- Francisco Javier J Martínez Noguera, Study chair, Research Center for High Performance Sport. Catholic University of Murcia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06639789
- Sponsor's protocol ID
- CE052416
- Acronym
- PERB12
- Status last verified
- Oct 2024
- First submitted
- 1 Sep 2024
- Last updated
- 15 Oct 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Oct 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the Effect of a New Formulation of Vitamin B12 on Physical and Mental Performance in Trained Cyclists.
- ClinicalTrials.gov ID
- NCT06639789
- Acronym / sponsor ID
- PERB12 / CE052416
- Conditions
- Performance Enhancing Product Use
- Keywords
- Anaerobic performance, Power, Mental fatigue, Vitamins, Recovery
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 18 participants (estimated)
- Lead sponsor
- Francisco Javier Martínez NogueraUniversity, hospital or other
- Collaborators
- Universidad Católica San Antonio de Murcia
- Study start
- 1 Jul 2024 (actual)
- Primary completion
- 30 Nov 2024 (estimated)
- Study completion
- 31 Dec 2024 (estimated)
- First posted
- 15 Oct 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This clinical study evaluates the effect of acute intake of a new vitamin B12 formulation on anaerobic and cognitive performance variables. One of the limiting factors for the potential beneficial effects of vitamin B12 is its bioavailability. This new formula improves this aspect, so that by improving plasma levels of B12 we will be able to relate whether this situation may be related to improved performance or cognitive tasks.
Detailed description
Participants
All participants were informed about the procedures and provided signed informed consent. The study was conducted in accordance with the guidelines of the Declaration of Helsinki Declaration for Research Involving Human Subjects and the protocol was approved by the Institutional Review/Ethics Committee of the Catholic University of Murcia (Code: CE052416).
Study design
Randomized, double-blind, placebo-controlled, crossover clinical trial with 2 study groups (vitamin B12 and placebo). Cyclists were instructed to take the supplement (vitamin B12 or placebo) with breakfast on the three days before the tests and 3h before the test day, and to continue with their usual diet and training programme. Subjects in both groups were instructed not to consume vitamin B12-rich foods for 7 days before and during the study. Between each intervention (B12 and Placebo) there was a 7-day washout period.
Procedures
Participants visited the laboratory on three occasions. Visit 1 consisted of a medical examination and a blood draw to determine health status. At visits 2 and 3, a 24-hour diet reminder and a Wingate test, mental fatigue test and venous blood draw were performed. The sports nutritionist prescribed a standardized breakfast before each testing session (visits 2 and 3).
Pre- and post-evaluation test
Visit 1:
Health status blood test: A general blood test will be performed both pre- and post-supplementation. The blood will be drawn through a vein (fasting).
Medical examination: A medical history of family and personal history, an electrocardiogram (ECG) at rest and a medical examination (auscultation, blood pressure, etc.) will be carried out to certify that the person is healthy and does not present a risk to participate in the study (Fasting).
Body composition by absorptiometric densitometry (DXA): A body composition test will be performed using the double energy absorptiometric densitometry technique (X-rays), with the aim of determining parameters of fat mass, fat-free mass and fat percentage. In addition, anthropometry will also be used to determine changes in body composition (fat and muscle mass) (Fasting).
Visits 2 and 3:
Anaerobic power and mechanical power output: After a standardised breakfast, a Wingate test was performed on a cycle ergometer. The Wingate test (WAnT) consisted of a 30 s sprint on a cycle ergometer (Monark Ergomedic 894E Peak Bike, Vansbro, Sweden). Breaking strength was held constant at 7.5% of each individual's body mass. All participants were verbally encouraged to pedal as fast as possible throughout the sprint.
Mental fatigue test: All participants will be tested for the evaluation of reaction time to a sequence of lights set by the investigator before and after the performance test.
Biochemical markers: A venous blood draw will be performed by medical personnel before and after the performance test, in which vitamin B12, creatine kinase and lactate dehydrogenase levels will be analyzed.
All data of the subjects who participated in the study were stored in a computer system with a security key. In addition, some of the data was also recorded on paper and kept under lock and key, accessible only to the researchers of this project.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
- Model description
- A randomized crossover study will be conducted in which 18 subjects will perform the following conditions: B12) 1 mg/d vitamin B12; PLA) 200 mg/d placebo (microcrystalline cellulose) 3 days before physical and cognitive performance tests.
| Arm | Type | Receives |
|---|---|---|
| Vitamin B12 (B12) | Experimental | Dietary Supplement: Vitamin B12 (B12)Subjects in this group will intake 1 mg/day of vitamin B12 three days before the tests. |
| PLACEBO (PLA) | Placebo comparator | Dietary Supplement: PLACEBO (PLA)Subjects in this group will intake 200 mg/day of microcrystalline cellulose three days before the tests. |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Male cyclists who have competed in both junior and amateur categories.
- Cycling between 6-15 hours of training per week.
- BMI between 18-25 kg/m2.
Key exclusion criteria (5 listed)
- Smokers or regular alcohol drinkers.
- Persons suffering from a metabolic, cardiorespiratory or digestive pathology or anomaly.
- digestive system.
- People who have suffered an injury in the last 6 months that limits the performance of the study tests. of the study tests.
- People taking supplements or medication in the 2 weeks before the start of the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Vitamin B12 (B12)The new formulation of vitamin B12 will be ingested 3 days before and on the day of testing (3 hours before). | Dietary supplement | Vitamin B12 (B12) |
| PLACEBO (PLA)The placebo will be ingested 3 days before and the same day of the tests (3 hours before). | Dietary supplement | PLACEBO (PLA) |
Primary outcome
Wingate test
Time frame: Throughout study completion, an average of 3 weeks
This test consists of 5 efforts of 30 seconds at maximum intensity with a recovery of 3 minutes on a bike. In this test the peak and average power of each effort and the total average will be evaluated. In addition, the time to maximum peak power and the fatigue index.
3 secondary outcomes
Mental fatigue test
Time frame: Throughout study completion, an average of 3 weeks
Biochemical markers
Time frame: Throughout study completion, an average of 3 weeks
Sleep Quality Questionnaire (Pittsburgh)
Time frame: Throughout study completion, an average of 3 weeks
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Oct 2024.
Related trials for Performance Enhancing Product Use
Active, not recruitingEarly Phase 1
A Comparison of the Physiological and Behavioral Effects of Suvorexant and Zolpidem in Healthy Volunteers: A Randomized, Double-blind, Placebo Controlled Study
Performance Enhancing Product Use
Enrolling by invitation
Optimizing Volunteer Comfort for Transcranial Electrical Stimulation (TES): An Assessment
Performance Enhancing Product Use, Sleep
RecruitingObservational study
Prospective, Longitudinal Study on FItness DOping in DenmarK
Anabolic Steroid Overdose, Infertility
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Francisco Javier J Martínez Noguera study chair
Research Center for High Performance Sport. Catholic University of Murcia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Vitamin B12 (B12) in people with Performance Enhancing Product Use, run by Francisco Javier Martínez Noguera at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 15 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Francisco Javier FJ Martínez Noguera, PhD ((+34) 968278566, fjmartinez3@ucam.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Wingate test (time frame: Throughout study completion, an average of 3 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Oct 2024.